Collegium Retained Earnings vs Current Deferred Revenue Analysis

COLL Stock

USD 32.47 1.20 3.56%

Collegium Pharmaceutical financial indicator trend analysis is way more than just evaluating Collegium Pharmaceutical prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Collegium Pharmaceutical is a good investment. Please check the relationship between Collegium Pharmaceutical Retained Earnings and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

Retained Earnings vs Current Deferred Revenue

Retained Earnings vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Collegium Pharmaceutical Retained Earnings account and Current Deferred Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Collegium Pharmaceutical's Retained Earnings and Current Deferred Revenue is -0.92. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Collegium Pharmaceutical, assuming nothing else is changed. The correlation between historical values of Collegium Pharmaceutical's Retained Earnings and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Collegium Pharmaceutical are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Retained Earnings i.e., Collegium Pharmaceutical's Retained Earnings and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

-0.92

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Collegium Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Collegium Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.At this time, Collegium Pharmaceutical's Tax Provision is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.37 this year, although the value of Selling General Administrative will most likely fall to about 97.6 M.

	2021	2022	2023	2024 (projected)
Interest Expense	21.0M	63.2M	83.3M	87.5M
Depreciation And Amortization	68.9M	138.9M	149.3M	156.7M

Interest Expense Depreciation And Amortization

Collegium Pharmaceutical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Treasury Stock	Short Term Debt
Total Assets		0.96	0.81	0.94	0.81	0.77	0.8	0.86	-0.53	0.42	0.76	0.98	0.33	0.21	0.97	0.87	0.71	0.75	0.96	0.39	0.69	0.99	0.93	0.96	-0.78	0.95
Short Long Term Debt Total	0.96		0.66	0.85	0.68	0.64	0.68	0.97	-0.34	0.27	0.59	0.98	0.23	0.1	1.0	0.74	0.55	0.58	0.99	0.56	0.52	0.97	0.82	0.87	-0.63	0.98
Other Current Liab	0.81	0.66		0.96	0.62	0.83	0.69	0.51	-0.59	0.39	0.73	0.71	0.3	0.22	0.71	0.9	0.68	0.76	0.64	-0.11	0.65	0.8	0.88	0.9	-0.81	0.75
Total Current Liabilities	0.94	0.85	0.96		0.7	0.83	0.75	0.72	-0.56	0.4	0.76	0.88	0.31	0.18	0.88	0.92	0.7	0.77	0.83	0.15	0.68	0.94	0.93	0.97	-0.82	0.9
Total Stockholder Equity	0.81	0.68	0.62	0.7		0.69	0.83	0.51	-0.73	0.63	0.94	0.76	0.46	0.4	0.7	0.83	0.91	0.92	0.72	0.25	0.89	0.74	0.8	0.83	-0.74	0.63
Other Liab	0.77	0.64	0.83	0.83	0.69		0.79	0.49	-0.8	0.58	0.75	0.7	0.36	0.24	0.66	0.78	0.77	0.86	0.65	0.14	0.81	0.75	0.84	0.82	-0.86	0.63
Property Plant And Equipment Net	0.8	0.68	0.69	0.75	0.83	0.79		0.56	-0.7	0.74	0.79	0.78	0.49	0.43	0.7	0.7	0.75	0.84	0.74	0.31	0.8	0.77	0.92	0.78	-0.92	0.61
Net Debt	0.86	0.97	0.51	0.72	0.51	0.49	0.56		-0.13	0.13	0.38	0.93	0.15	0.03	0.95	0.55	0.34	0.37	0.96	0.64	0.32	0.9	0.7	0.72	-0.49	0.93
Retained Earnings	-0.53	-0.34	-0.59	-0.56	-0.73	-0.8	-0.7	-0.13		-0.83	-0.84	-0.42	-0.41	-0.13	-0.35	-0.7	-0.9	-0.89	-0.38	-0.12	-0.95	-0.47	-0.64	-0.66	0.79	-0.3
Accounts Payable	0.42	0.27	0.39	0.4	0.63	0.58	0.74	0.13	-0.83		0.68	0.37	0.28	0.29	0.26	0.44	0.7	0.72	0.34	0.34	0.79	0.38	0.55	0.48	-0.82	0.15
Cash	0.76	0.59	0.73	0.76	0.94	0.75	0.79	0.38	-0.84	0.68		0.66	0.4	0.28	0.61	0.9	0.97	0.96	0.62	0.12	0.93	0.7	0.79	0.86	-0.8	0.58
Non Current Assets Total	0.98	0.98	0.71	0.88	0.76	0.7	0.78	0.93	-0.42	0.37	0.66		0.33	0.22	0.99	0.77	0.61	0.66	0.99	0.49	0.6	0.99	0.89	0.9	-0.72	0.95
Non Currrent Assets Other	0.33	0.23	0.3	0.31	0.46	0.36	0.49	0.15	-0.41	0.28	0.4	0.33		-0.12	0.28	0.36	0.37	0.4	0.27	-0.16	0.45	0.3	0.46	0.32	-0.4	0.22
Other Assets	0.21	0.1	0.22	0.18	0.4	0.24	0.43	0.03	-0.13	0.29	0.28	0.22	-0.12		0.13	0.18	0.25	0.38	0.15	-0.09	0.26	0.17	0.33	0.19	-0.32	0.05
Long Term Debt	0.97	1.0	0.71	0.88	0.7	0.66	0.7	0.95	-0.35	0.26	0.61	0.99	0.28	0.13		0.77	0.56	0.6	0.99	0.48	0.54	0.98	0.85	0.89	-0.65	0.99
Cash And Short Term Investments	0.87	0.74	0.9	0.92	0.83	0.78	0.7	0.55	-0.7	0.44	0.9	0.77	0.36	0.18	0.77		0.86	0.86	0.72	0.03	0.81	0.84	0.86	0.97	-0.75	0.79
Common Stock Total Equity	0.71	0.55	0.68	0.7	0.91	0.77	0.75	0.34	-0.9	0.7	0.97	0.61	0.37	0.25	0.56	0.86		0.96	0.57	0.17	0.97	0.65	0.73	0.81	-0.77	0.53
Common Stock Shares Outstanding	0.75	0.58	0.76	0.77	0.92	0.86	0.84	0.37	-0.89	0.72	0.96	0.66	0.4	0.38	0.6	0.86	0.96		0.61	0.12	0.97	0.7	0.82	0.84	-0.85	0.56
Non Current Liabilities Total	0.96	0.99	0.64	0.83	0.72	0.65	0.74	0.96	-0.38	0.34	0.62	0.99	0.27	0.15	0.99	0.72	0.57	0.61		0.58	0.56	0.97	0.84	0.86	-0.67	0.95
Other Current Assets	0.39	0.56	-0.11	0.15	0.25	0.14	0.31	0.64	-0.12	0.34	0.12	0.49	-0.16	-0.09	0.48	0.03	0.17	0.12	0.58		0.19	0.42	0.2	0.23	-0.24	0.4
Other Stockholder Equity	0.69	0.52	0.65	0.68	0.89	0.81	0.8	0.32	-0.95	0.79	0.93	0.6	0.45	0.26	0.54	0.81	0.97	0.97	0.56	0.19		0.64	0.75	0.78	-0.82	0.48
Total Liab	0.99	0.97	0.8	0.94	0.74	0.75	0.77	0.9	-0.47	0.38	0.7	0.99	0.3	0.17	0.98	0.84	0.65	0.7	0.97	0.42	0.64		0.92	0.95	-0.76	0.97
Property Plant And Equipment Gross	0.93	0.82	0.88	0.93	0.8	0.84	0.92	0.7	-0.64	0.55	0.79	0.89	0.46	0.33	0.85	0.86	0.73	0.82	0.84	0.2	0.75	0.92		0.93	-0.9	0.82
Total Current Assets	0.96	0.87	0.9	0.97	0.83	0.82	0.78	0.72	-0.66	0.48	0.86	0.9	0.32	0.19	0.89	0.97	0.81	0.84	0.86	0.23	0.78	0.95	0.93		-0.82	0.89
Treasury Stock	-0.78	-0.63	-0.81	-0.82	-0.74	-0.86	-0.92	-0.49	0.79	-0.82	-0.8	-0.72	-0.4	-0.32	-0.65	-0.75	-0.77	-0.85	-0.67	-0.24	-0.82	-0.76	-0.9	-0.82		-0.59
Short Term Debt	0.95	0.98	0.75	0.9	0.63	0.63	0.61	0.93	-0.3	0.15	0.58	0.95	0.22	0.05	0.99	0.79	0.53	0.56	0.95	0.4	0.48	0.97	0.82	0.89	-0.59

Click cells to compare fundamentals

Collegium Pharmaceutical Account Relationship Matchups

Collegium Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	306.3M	643.8M	692.1M	1.2B	1.1B	1.2B
Short Long Term Debt Total	21.6M	266.6M	258.8M	872.8M	674.3M	708.0M
Other Current Liab	153.1M	108.3M	147.8M	66.9M	264.9M	278.1M
Total Current Liabilities	197.3M	191.2M	230.4M	270.1M	457.9M	480.8M
Total Stockholder Equity	87.4M	186.0M	202.9M	194.8M	195.4M	127.6M
Property Plant And Equipment Net	20.9M	27.4M	27.1M	26.4M	22.0M	13.8M
Net Debt	(148.4M)	92.5M	72.3M	699.1M	435.3M	457.1M
Retained Earnings	(359.9M)	(333.1M)	(256.3M)	(281.3M)	(233.2M)	(244.8M)
Accounts Payable	39.7M	34.7M	33.4M	39.6M	8.7M	8.3M
Cash	170.0M	174.1M	186.4M	173.7M	238.9M	146.7M
Non Current Assets Total	50.6M	366.0M	376.5M	754.1M	605.7M	636.0M
Non Currrent Assets Other	178K	2.7M	87K	100K	825.0K	488K
Other Assets	178K	11.1K	942.7M	19.3M	22.2M	21.1M
Long Term Debt	7.7M	209.6M	201.6M	538.5M	483.8M	508.0M
Cash And Short Term Investments	170.0M	174.1M	186.4M	173.7M	310.5M	326.1M
Common Stock Total Equity	34K	35K	36K	37K	42.6K	29.4K
Common Stock Shares Outstanding	33.5M	35.2M	41.0M	33.8M	41.8M	30.1M
Liabilities And Stockholders Equity	306.3M	643.8M	692.1M	1.2B	1.1B	1.2B
Non Current Liabilities Total	21.6M	266.6M	258.8M	709.2M	490.0M	514.5M
Other Current Assets	141K	60K	27K	16.7M	93K	88.4K
Other Stockholder Equity	447.3M	519.1M	459.2M	476.1M	428.6M	374.3M
Total Liab	218.9M	457.8M	489.1M	979.3M	947.9M	995.3M
Property Plant And Equipment Gross	20.9M	27.4M	27.1M	26.4M	31.7M	33.3M
Total Current Assets	255.7M	277.9M	315.5M	420.0M	537.6M	564.5M
Accumulated Other Comprehensive Income	(1.7M)	(1.8M)	(2.3M)	0.0	14K	14.7K
Short Term Debt	4.5M	48.2M	49.2M	163.6M	184.3M	193.5M
Common Stock	34K	35K	36K	37K	38K	30.5K
Property Plant Equipment	20.9M	19.0M	19.5M	19.5M	22.4M	23.6M
Net Tangible Assets	57.9M	(149.9M)	(65.8M)	(506.3M)	(455.7M)	(432.9M)
Net Receivables	73.0M	83.3M	105.8M	183.1M	179.5M	188.5M
Inventory	9.6M	15.6M	17.4M	46.5M	32.3M	33.9M
Short Long Term Debt	3.8M	47.5M	48.4M	162.5M	183.3M	192.5M
Intangible Assets	29.5M	335.9M	268.7M	567.5M	421.7M	442.8M
Retained Earnings Total Equity	(359.9M)	(333.1M)	(256.3M)	(281.3M)	(253.2M)	(265.9M)
Long Term Debt Total	7.7M	209.6M	201.6M	538.5M	619.2M	650.2M
Capital Surpluse	447.3M	519.1M	502.1M	538.1M	618.8M	468.8M
Non Current Liabilities Other	9.4M	8.8M	8.0M	7.1M	8.2M	6.2M

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Collegium Pharmaceutical using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Fix portfolios for free

When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:

How To Invest In Collegium

Details

Is Collegium Stock a good investment?

Details

What is Collegium Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Collegium Stock analysis

When running Collegium Pharmaceutical's price analysis, check to measure Collegium Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collegium Pharmaceutical is operating at the current time. Most of Collegium Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Collegium Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collegium Pharmaceutical's price. Additionally, you may evaluate how the addition of Collegium Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon

Is Collegium Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

51.976

Earnings Share

2.51

Revenue Per Share

17.054

Quarterly Revenue Growth

0.001

Return On Assets

0.1056

The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Collegium Retained Earnings vs Current Deferred Revenue Analysis

Retained Earnings vs Current Deferred Revenue

Retained Earnings vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Retained Earnings

Current Deferred Revenue

Collegium Pharmaceutical fundamental ratios Correlations

Collegium Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Collegium Pharmaceutical fundamental ratios Accounts

Becoming a Better Investor with Macroaxis

Build Optimal Portfolios

Align your risk with return expectations

Complementary Tools for Collegium Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Long Term Debt	+ 0.99	Non Current Assets Total
Non Current Liabilities Total	+ 0.99	Non Current Assets Total
Total Liab	+ 0.99	Non Current Assets Total

Other Stockholder Equity	- 0.95	Retained Earnings
Treasury Stock	- 0.92	Property Plant And Equipment Net
Treasury Stock	- 0.9	Property Plant And Equipment Gross
Common Stock Total Equity	- 0.9	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Treasury Stock	- 0.86	Other Liab